EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

Third, Poseidon’s TCEs have multiple binding modalities to enhance tumor selectivity and address heterogeneous antigen expression ... killing and broad cytokine release. The inability of ...

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors — a smart fighter that destroys ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

C.M. Laumont et al., “Noncoding regions are the main source of targetable tumor-specific antigens,” Sci Transl Med, 10:eaau5516, 2019. In pursuit of safe and effective cancer therapies, researchers ...

American Indian and Black patients were 23% less likely to have an elevated cancer antigen (CA)-125 level at diagnosis. Current CA-125 thresholds may miss racially and ethnically diverse patients ...

By fighting off pathogens, the specialized cells of our immune systems help to keep us healthy and free of infectious diseases. Immunotherapies teach those same cells to recognize and destroy cancer.

It is formulated with mRNA solution encoding multiple tumor-associated antigens (TAAs), encapsulated ... Forward-Looking Statements This news release may make statements that constitute forward ...